A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.34.15_SUPPL.TPS2608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

  2024cites this paper
• Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

  2022cites this paper
• Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

  2021cites this paper
• A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

  2020cites this paper
• The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.

  2020cites this paper
• Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition

  2018cites this paper
• [Impairment of DNA damage response and cancer].

  2017cites this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cites this paper
• DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

  2017cites this paper